Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other stocks also dropped premarket.
Stocks · News reference
Earnings Scheduled For September 25, 2026
Companies Reporting Before The Bell • Tamboran Resources (NYSE:TBN) is estimated to report quarterly loss at $0.30 per share on revenue of $3.82 million. Companies Reporting After The Bell • Inventiva (NASDAQ:IVA) is
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guggenheim Maintains Buy on Inventiva, Raises Price Target to $14
Guggenheim analyst Seamus Fernandez maintains Inventiva (NASDAQ:IVA) with a Buy and raises the price target from $11 to $14.
Inventiva Completes Final 72-Week NATiV3 Patient Visit With 1,419 Patients Enrolled, Topline Results Expected Q4 2026
Last patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the exploratory cohortTopline results of NATiV3 expected in Q4 2026September investor conference
Tamboran Resources Q4 2026 Earnings Call Transcript
On Friday, Tamboran Resources (NYSE:TBN) discussed fourth-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial
Tamboran Resources Q4 EPS $(0.06) Beats $(0.30) Estimate
Tamboran Resources (NYSE:TBN) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.30) by 80 percent. This is a 90.77 percent increase over losses of $(0.65) per share from the
Stock Market Today: Dow, S&P 500, Nasdaq Futures Rise Amid Optimism Following Iran’s Offer To Reopen Strait of Hormuz — AKAM, COST, SCHL In Focus (UPDATED)
U.S. stocks eye a higher open as Iran signals possible Hormuz reopening and nuclear talks; Akamai surges on $11.6B Anthropic deal.